Metabolic insights from a GHSR-A203E mutant mouse model

Torz, Lola J.; Osborne-Lawrence, Sherri; Rodriguez, Juan; He, Zhenyan; Paula Cornejo, Maria; Roman Mustafa, Emilio; Jin, Chunyu; Petersen, Natalia; Hedegaard, Morten A.; Nybo, Maja; Martinez Damonte, Valentina; Metzger, Nathan P.; Mani, Bharath K.; Williams, Kevin W.; Raingo, Jesica; Perello, Mario; Holst, Birgitte; Zigman, Jeffrey M.

Published in:
Molecular Metabolism

DOI:
10.1016/j.molmet.2020.101004

Publication date:
2020

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY-NC-ND

Citation for published version (APA):
Torz, L. J., Osborne-Lawrence, S., Rodriguez, J., He, Z., Paula Cornejo, M., Roman Mustafa, E., ... Zigman, J. M. (2020). Metabolic insights from a GHSR-A203E mutant mouse model. Molecular Metabolism, 39, [101004]. https://doi.org/10.1016/j.molmet.2020.101004

Download date: 06. Nov. 2020
Metabolic insights from a GHSR-A203E mutant mouse model

Lola J. Torz1,5, Sherri Osborne-Lawrence2, Juan Rodriguez2, Zhenyan He2, María Paula Cornejo3, Emilio Román Mustafá1, Chunya Jin5, Natalia Petersen1, Morten A. Hedegaard1, Maja Nybo5, Valentina Martínez Damonte1, Nathan P. Metzger2, Bharath K. Mani2, Kevin W. Williams2, Jesica Raingo4, Mario Perello3, Birgitte Holst1,5, Jeffrey M. Zigman2,*, Jeffrey M. Zigman2,*.

ABSTRACT

Objective: Binding of ghrelin to its receptor, growth hormone secretagogue receptor (GHSR), stimulates GH release, induces eating, and increases blood glucose. These processes may also be influenced by constitutive (ghrelin-independent) GHSR activity, as suggested by findings in short people with naturally occurring GHSR-A204E mutations and reduced food intake and blood glucose in rodents administered GHSR inverse agonists, both of which impair constitutive GHSR activity. In this study, we aimed to more fully determine the physiologic relevance of constitutive GHSR activity.

Methods: We generated mice with a GHSR mutation that replaces alanine at position 203 with glutamate (GHSR-A203E), which corresponds to the previously described human GHSR-A204E mutation, and used them to conduct ex vivo neuronal electrophysiology and in vivo metabolic assessments. We also measured signaling within COS-7 and HEK293T cells transfected with wild-type GHSR (GHSR-WT) or GHSR-A203E constructs.

Results: In COS-7 cells, GHSR-A203E resulted in lower baseline IP3, accumulation than GHSR-WT; ghrelin-induced IP3; accumulation was observed in both constructs. In HEK293T cells co-transfected with voltage-gated CaV2.2 calcium channel complex, GHSR-A203E had no effect on basal Ca2.2 current density while GHSR-WT did; both GHSR-A203E and GHSR-WT inhibited Ca2.2 current in the presence of ghrelin. In cultured hypothalamic neurons from GHSR-A203E and GHSR-deficient mice, native calcium currents were greater than those in neurons from wild-type mice; ghrelin inhibited calcium currents in cultured hypothalamic neurons from both GHSR-A203E and wild-type mice. In brain slices, resting membrane potentials of arcuate NPY neurons from GHSR-A203E mice were hyperpolarized compared to those from wild-type mice; the same percentage of arcuate NPY neurons from GHSR-A203E and wild-type mice depolarized upon ghrelin exposure. The GHSR-A203E mutation did not significantly affect body weight, body length, or femur length in the first ~6 months of life, yet these parameters were lower in GHSR-A203E mice after 1 year of age. During a 7-d 60% caloric restriction regimen, GHSR-A203E mice lacked the usual marked rise in plasma GH and demonstrated an exaggerated drop in blood glucose. Administered ghrelin also exhibited reduced orexigenic and GH secretagogue efficacies in GHSR-A203E mice.

Conclusions: Our data suggest that the A203E mutation ablates constitutive GHSR activity and that constitutive GHSR activity contributes to the native depolarizing conductance of GHSR-expressing arcuate NPY neurons. Although the A203E mutation does not block ghrelin-evoked signaling as assessed using in vitro and ex vivo models, GHSR-A203E mice lack the usual acute food intake response to administered ghrelin in vivo. The GHSR-A203E mutation also blunts GH release, and in aged mice leads to reduced body length and femur length, which are consistent with the short stature of human carriers of the GHSR-A204E mutation.

Keywords Ghrelin; Constitutive activity; Growth hormone; GH

1. INTRODUCTION

In their seminal paper, Kojima et al. described the identification of ghrelin as an endogenous agonist for GHSR that potently stimulates GH secretion [1]. Ghrelin also exerts key orexigenic and glucoregulatory actions, the latter of which prevent life-threatening hypoglycemia in starvation-like settings [2,3]. While binding of ghrelin to GHSR is required for ghrelin action, GHSR signaling also occurs via a ghrelin-independent, constitutive manner [3–7]. As first reported in 2003, transient transfection of cultured cells with increasing amounts of
human GHSR dose-dependently increases signaling via the Gq/ phospholipase C pathway, increasing inositol phosphate (IP) accumulation and inducing cAMP response element-dependent activity [9]. These in vitro indications of high constitutive GHSR activity have been extended to other signaling systems including reduced β-arrestin recruitment and those involving voltage-gated CaV2.2 calcium channels, among others [9–14]. Indeed, transfection with GHSR increases basal signaling above mock-transfected cells to approximately 50% of GHSR’s maximal signaling capacity [13].

Of interest, studies with administered GHSR inverse agonists, which are defined as such by their capacity to inhibit constitutive GHSR activity, suggest physiologically significant effects of constitutive GHSR activity. For example, infusion in rats of the high-potency GHSR inverse agonist [D-Arg⁵, D-Phε⁸, D-Trp¹²,T⁶, Leu¹¹]-substance P [8] decreased food intake and body weight [15]. Intrarenal infusion of the same compound prevented hypertension in uninephrectomized Dahl salt-sensitive rats fed high-fat diets [16]. Administration of the GHSR inverse agonist K-(D-1-Nal)-FwLL-NH₂, but not administration of the GHSR antagonist [D-Lys³]-GHRP-6 or JM29599, reduced compensatory hyperphagia following a 48 h fast and binge-like high-fat intake in mice [17,18]. Administration of GHSR inverse agonists GHSR-IA1 and/or GHSR-IA2 reduced food intake and increased energy expenditure in lean C57BL/6 mice, reduced food intake, body weight, and blood glucose in diet-induced obese C57BL/6J mice, and improved oral glucose tolerance in Zucker diabetic fatty rats [19]. Additionally, the GHSR inverse agonist PF-05190457 decreased postprandial blood glucose and delayed gastric emptying in human subjects, although it also blocked administered ghrelin-induced GH secretion [20]. This latter finding is a reminder that most inverse agonists also act as antagonists, and furthermore, that many pharmacologic GHSR ligands exhibit differential functional signaling and downstream signaling bias [12,21–23].

Also suggesting a potentially important physiological role for constitutive GHSR activity, liver-enriched antimalarial peptide-2 (LEAP2) was recently identified as a second endogenous GHSR ligand, one with both GHSR antagonist and inverse agonist activities [24–27]. As such, LEAP2 not only blocks ghrelin-induced GHSR signaling in vitro, ghrelin-induced membrane depolarization of arcuate NPY neurons, and ghrelin-induced food intake and GH secretion, but also reduces constitutive IP accumulation in GHSR-transfected cells and hyperpolarizes arcuate NPY neurons [24–27]. It has been proposed that LEAP2’s actions as a GHSR antagonist and inverse agonist become pronounced when its plasma levels increase, as occurs in obesity, especially postprandially [24,26].

Notably, a naturally occurring GHSR mutation that impairs constitutive GHSR activity was reported by Pantel et al. [28]. This GHSR-A204E mutation, which was identified in two unrelated Moroccan families, segregated with short stature in a dominant manner with a penetrance of ~70% [21,28]. In vitro studies revealed that the GHSR-A204E mutant exhibited markedly reduced basal Gqα-mediated signaling, a near total reduction in β-arrestin recruitment, and resistance to the usual signaling effects of [D-Arg⁵, D-Phε⁸, D-Trp¹²,T⁶, Leu¹¹]-substance P, all of which suggest lost constitutive GHSR activity [14,21,28]. However, ghrelin binding and ghrelin-induced Gqα-coupled signaling were unaltered in GHSR-A204E-transfected cells [28]. Thus, the short stature associated with the GHSR-A204E mutation was attributed to lost constitutive GHSR activity [21,28]. Interestingly, several family members carrying the GHSR-A204E mutation were also overweight or obese [28], and another study independently reported the GHSR-A204E mutation in an obese child [29]. Other naturally occurring GHSR mutations causing decreased constitutive GHSR activity and short stature have since been described [21,29,30]. In the current study, we further investigated the physiological significance of constitutive GHSR activity by introducing an A203E mutation (the mouse correlate of the previously described human GHSR-A204E mutation) into the mouse GHSR sequence.

2. MATERIALS AND METHODS

2.1. Signaling studies in COS-7 cells

In Copenhagen, COS-7 cells (ATCC, Wesel, Germany) were grown in Dulbecco’s modified Eagle’s medium (DMEM) 1885 containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillin/streptomycin at 37 °C in a 10% CO₂ incubator. Cells seeded at a density of 20,000 cells/well in a 96-well plate were transiently transfected with 0.4 μg of pcMV-Tag2B plasmid (Stratagene, La Jolla, CA, USA) DNA per well by calcium phosphate precipitation using a method modified from [31]. The plasmids contained either GHSR-WT or GHSR-A203E constructs, which were generated using the PCR overlap extension method with Pfu polymerase (Promega, Waltham, MA, USA) as previously described [14]. The constructs’ sequences were verified by DNA sequencing (Eurofins MWG Operon, Ebersberg, Germany). Five h after transfection, the medium was exchanged for growth medium (Dulbecco’s modified Eagle’s medium (DMEM) 1885 containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillin/streptomycin) containing 5 μM/mL of Myo[2–5H(N)]-inositol (PerkinElmer, Skovlunde, Denmark), and the cells were incubated for 2 d. Signaling studies were conducted by removing the medium, washing the cells once with 1x HBSS buffer, and then incubating at 37 °C in 100 μL HBSS buffer containing 10 mM LiCl and a range of different ghrelin (Polypeptide, Inc., Hillerd, Denmark) concentrations. After 90 min incubation, the cells were placed on ice, lysed with ice-cold 10 mM formic acid for at least 30 min, transferred to 96-well plates containing SPA-YSI beads (PerkinElmer), shaken at full speed on a plate shaker (PerkinElmer) for at least 10 min, centrifuged for 5 min at 1500 rpm, and incubated for 4 h at room temperature. IP₃ accumulation was measured using a Microbeta (PerkinElmer). For each replicate, the Eₘₐₓ values of the GHSR-WT construct were normalized and set to 100% for further analysis.

2.2. Whole-cell patch-clamp in HEK293T cells

In La Plata, HEK293T cells (kindly provided by Dr. Diane Lipscombe, Brown University, Providence, RI, USA) were grown in DMEM (Gibco Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FBS (Interneogenics, Mercedes, Buenos Aires, Argentina). The cells were transiently transfected with plasmids containing GHSR-WT or GHSR-A203E and plasmids containing voltage-gated calcium channel subunits CaV₂.2 (Cacna1b, GenBank access #AF055477) with auxiliary subunits Cacnβ3 (Cacnb3, GenBank access #M88751) and Cacnβ2.1 (Cacnb2, GenBank access #AF286488) using Lipofectamine 2000 (Invitrogen). CaV₂.2 subunits were kindly provided by Dr. Lipscombe and GHSR-WT was kindly provided by Dr. Jacky Marie, University of Montpellier, Montpellier, France). The GHSR-A203E construct was generated through directed mutagenesis of a mouse GHSR (MC212500, OriGene, Rockville, MD, USA) containing plasmid by Dr. Silvia Rodriguez at the IMBICE, La Plata. For experiments lacking one or more plasmids, the cells were transfected with empty plasmid pCDNA3.1 (+) (Invitrogen) to maintain an equivalent total plasmid amount in the transfection mix and an eGFP-containing plasmid to identify transfected cells. After transfection, the cells were cultured

original article
for 24 h, dispersed with 0.25 mg/mL trypsin, rinsed twice in DMEM, and maintained at room temperature in DMEM for whole-cell patch-clamp recordings. The internal pipette solution contained (in mM) 134 CsCl, 10 E GTA, 1 EDTA, 10 HEPES, and 4 MgATP (pH 7.2 with CsOH). The external solution contained (in mM) 2 CaCl₂, 1 MgCl₂, 10 HEPES, and 140 choline chloride (pH 7.4 with CsOH). The cells were maintained at –100 mV to remove closed-state inactivation [32]. The test-pulse protocol consisted of square pulses applied from –100 to +10 mV every 10 s. Electrophysiological recordings were acquired using an Axopatch 200 amplifier (Molecular Devices). Data were sampled at 20 kHz and filtered at 10 kHz (–3 dB) using PCLAMP8.2 software (Molecular Devices). Recording electrodes with resistances between 2 and 5 MΩ were used filled with internal solution. Series resistances less of 6 MΩ were admitted and compensated to 80% with a 10 µs lag time. Current leak was subtracted online using a P/2-4 protocol. All of the recordings were obtained at room temperature (23 °C).

2.3. Generation of GHSR-A203E and GHSR-A203E-null mouse lines
The targeting construct used to generate our previously reported GHSR-null mouse line [33], which contains a loxP-flanked transcriptional blocking cassette (TBC) within an intron located downstream of the transcriptional start site and upstream of the translational start site of the mouse Ghsr gene surrounding by Ghsr homology arms, was mutated using site-directed mutagenesis (QuickChange II XL Site-Directed Mutagenesis Kit, Agilent, Santa Clara, CA, USA). Plasmid containing the GHSR-null targeting construct was amplified by PCR using primers containing the desired mutation (underlined) at the codon for amino acid 203 (5’-GCCCAGGATGTCAGGTCGCTCTGAGGC-3’ and its reverse complement) digested with BsrGI and transformed into One Shot Top10 Competent Cells (Agilent). DNA from the resulting clones was sequenced to confirm the successful introduction of only the desired mutation. The resulting GHSR-A203E plasmid was submitted to the UT Southwestern Medical Center Transgenic Core Facility for gene targeting. Correctly targeted ES cell clones were identified by Southern blotting and PCR analyses as conducted originally for the GHSR-null line [1]. Two ES cell clones were sequenced to confirm the presence of the desired mutation and then sent for blastocyst injection. Germine transmission was established for both clones and the resulting mice were backcrossed once to C57Bl/6N. GHSR-A203E-null mice (harboring 2 copies of the Ghsr allele containing the loxP-flanked TBC + the A203E mutation) and their littermates, which included wild-type mice (harboring 2 copies of the wild-type Ghsr allele) and heterozygotes, were viable and born with the expected Mendelian distribution upon mating of heterozygotes, as confirmed by both Southern blotting analysis of genomic DNA and sequencing (data not shown).

Mice heterozygous for the GHSR-A203E-null allele from the initial backcross to C57Bl/6N were crossed to Zona Pellucida 3 (ZP3-cre) mice [34] to generate female breeders with one copy of the GHSR-A203E-null allele and one copy of the ZP3-cre transgene. As the ZP3-cre removed the TBC from the ova of the female breeders, when crossed to C57Bl/6N males, they resulted in progeny with one copy of the GHSR-A203E allele (the GHSR-A203E-null allele minus one loxP site and the TBC) and one copy of the ZP3-cre allele. Subsequent crosses to C57Bl/6N were conducted to remove ZP3-cre. Finally, mice heterozygous for the GHSR-A203E allele were crossed to each other to generate GHSR-A203E mice (harboring 2 copies of the Ghsr allele containing the A203E mutation) and their littermates, which included wild-type mice and heterozygotes. The study mice were derived from heterozygotes that had been backcrossed onto C57Bl/6N for 7 generations.

2.4. Mouse studies: general
Ex vivo studies were conducted using tissues taken from mice housed in La Plata (Figure 3) and Dallas (Figure 4). In vivo studies were conducted in Dallas (Figures 5, 7A, and 8) and Copenhagen (Figure 2B, C, 6, and 7B–G). The mice were housed at room temperature (Dallas: 21.5–22.5 °C; Copenhagen: 22 ± 2 °C; La Plata: 23 ± 2°C) using a 12 h light–dark cycle and provided ad libitum access to water and standard chow (Dallas: 2016 Teklad Global 16% Protein Rodent Diet (Envigo, Indianapolis, IN, USA); Copenhagen: Altromin 1314 (extruded form, Altromin GmbH & Co. KG, Im Seelenkamp, Germany); and La Plata: Gepsa Feeds (Grupo Pilar, Pilar, Argentina), except as noted. The animal procedures were approved by the Institutional Animal Care and Use Committee of UT Southwestern Medical Center, the Danish Working Environment Authority at University of Copenhagen, or the Institutional Animal Care and Use Committee of the IMBICE.

2.5. Whole-cell patch-clamp in cultured hypothalamic neurons
In La Plata, hypothalamic neuronal cultures were derived from GHSR-A203E, GHSR-A203E-null, and wild-type mice at embryonic days 16–18 as described in [35]. Hypothalami were removed from embryonic brains, placed in sterile Hanks’ solution, and rinsed twice in DMEM/F12 (Microvet, Buenos Aires, Argentina) pH 7.4 with CsOH. The cells were dissociated with 0.25 mg/mL trypsin (Microvet, Buenos Aires, Argentina) at 37 °C for 20 min and then 300 µL fetal bovine serum (FBS; Internegocios) and 0.28 mg/mL deoxyribonuclease I (Sigma–Aldrich, Buenos Aires, Argentina) were added. The cells were mechanically dissociated using several glass pipettes with consecutively smaller diameter tips. Overall, ~70,000 cells were plated on 12 mm diameter glass coverslips treated with poly-1-lysine (Sigma–Aldrich) and laid out over 24-well plates. The cells were incubated at 37 °C in a 95% air/5% CO₂ atmosphere with DMEM/F12 (Microvet) 1:1 medium supplemented with B27 supplement (1:50, Gibco, Thermo Fisher Scientific), 10% FBS, 0.25% glucose, 2 mM glutamine (Gibco), 3.3 µg/mL insulin (Novo Nordisk Pharmaceutical Industries, Inc., Buenos Aires, Argentina), 40 µg/mL gentamicin sulfate salt (Richet, Buenos Aires, Argentina), and 1% vitamin solution (Microvet). On the fourth day in culture, half of the incubating medium was replaced with fresh medium containing cytosine β-arabinofuranoside (Sigma–Aldrich) to reach a final concentration of 5 µM.

Barium currents of primary neuronal cultures were obtained following 7–15 days of culture. The neurons were patched in voltage-clamp whole-cell mode at a holding potential of ~80 mV, applying square test pulses to 0 mV for 20 ms every 10 s [36]. The internal pipette solution contained (mM) 134 CsCl, 10 EGTA, 1 EDTA, 10 HEPES, and 4 MgATP, pH 7.2 with CsOH. Neurons were bathed with high-sodium external solution containing (mM) 135 NaCl, 4.7 KCl, 1.2 MgCl₂, 2.5 CaCl₂, 10 HEPES, and 10 glucose pH 7.4 with NaOH. After obtaining the whole-cell configuration, Ca₂⁺ currents were recorded after replacing the external solution with a high-barium solution containing (mM) 10 BaCl₂, 110 choline chloride, 20 tetraethylammonium chloride, 1 MgCl₂, 10 HEPES, 10 glucose, and 0.001 tetrodotoxin (TTX; Sigma–Aldrich) pH 7.4 with CsOH. Electrophysiological recordings were acquired as described in Section 2.2.

2.6. Whole-cell patch-clamp in brain slices
In Dallas, GHSR-A203E mice were crossed to NPY-hrGFP mice (kindly provided by Dr. Joel Elmqquist (UT Southwestern Medical Center [37]) to generate GHSR-A203E and wild-type littermates with humanized Renilla reniformis green fluorescent protein-labeled NPY neurons. Recordings from NPY-hrGFP neurons within 250 µm thick coronal hypothalamic slice preparations from 8- to 12-week-old male mice
Figure 1: In vitro studies comparing signaling by GHSR-WT vs GHSR-A203E mutant. (A) Basal and ghrelin-induced IP3 accumulation in COS-7 cells expressing GHSR-WT (EC50 = 7.0 ± 0.8 × 10^-9 M; Emax = 99.3%) or GHSR-A203E (EC50 = 1.7 ± 0.1 × 10^-9 M; Emax = 88.7%) (n = 5). Data were analyzed by an unpaired Student's t-test for 0, 10^-6, and 10^-5 M concentrations of ghrelin. (B) Representative traces of CaV current and (C) mean CaV current values from HEK293T cells co-expressing CaV2.2 and its auxiliary subunits (CaVα2δ1 and CaVβ3) together with empty plasmid (control, n = 16) or GHSR-A203E (n = 4) or GHSR-WT (n = 4). Data were analyzed by Kruskal–Wallis ANOVA followed by Dunn's post hoc analysis. (D) Normalized representative traces of CaV current and (E) mean CaV current percentage of inhibition by ghrelin of HEK293T cells co-expressing CaV2.2 and its auxiliary subunits (CaVα2δ1 and CaVβ3) together with GHSR-A203E (n = 5) or GHSR-WT (n = 5), in the absence and presence of ghrelin (500 nM). Data were analyzed by unpaired Student's t-test. *P < 0.05, ****P < 0.0001, and n.s. = non-significant.
and data analysis were conducted as in [26,38,39]. The pipette solution for whole-cell recording contained (mmol/L) 120 K-gluconate, 10 KCl, 10 HEPES, 5 EGTA, 1 CaCl₂, 1 MgCl₂, 2 MgATP, and either 0.03 Alexa Fluor 594 or 0.03 Alexa Fluor 350 hydrazide dye (pH 7.3). Epifluorescence was briefly used to target fluorescent cells, at which time the light source was switched to infrared differential interference contrast imaging to obtain the whole-cell recording (Zeiss Axioskop FS2 Plus equipped with a fixed stage and a QuantEM:512SC electron-multiplying charge-coupled device camera). Electrophysiological signals were recorded using an Axopatch 700B amplifier (Molecular Devices, San Jose, CA, USA) low-pass filtered at 2–5 kHz and analyzed offline on a PC with pCLAMP programs (Molecular Devices). A drug effect was required to be temporally associated with peptide application, and the response had to be stable within a few minutes. A neuron was considered depolarized or hyperpolarized if a change in its membrane potential was at least 2 mV in amplitude.

2.7. Long-term feeding studies

Four-week-old mice were individually housed one week after weaning. In Dallas (Figure 5), body weight and food intake were monitored weekly at 9:00 am for 21 weeks. The cumulative feed efficiency was calculated by comparing the body weight at each weekly time point to the starting body weight and then dividing this body weight gain value by the energy content of the chow consumed over the same duration. Nose-to-anus body lengths of female mice were assessed by placing 25-week-old mice anesthetized with isoflurane prone on a ruler. In Copenhagen (Figure 6), body weights were measured at various time points between the ages of 21–66 weeks. Body lengths were assessed as previously described in anesthetized mice at 3 different time points. At 66 weeks of age, femurs and hypothalami were extracted from euthanized mice. Femur lengths were measured using calipers.

2.8. Administered ghrelin-induced food intake

In Dallas (Figure 7A), following the long-term feeding study, the 25-week-old male mice were handled for 3 days to acclimatize them, after which they were administered s.c. injections of saline, and then 0.1 mg/kg ghrelin 2 d later, followed by 1.0 mg/kg ghrelin 2 d afterward at 9:30 am. Two h intake of a standard chow pellet placed on the cage floor was determined after each injection. At 26 weeks of age, the males were anesthetized and nose-to-anus body lengths assessed as previously described. Femurs extracted from euthanized 26-week-old

Figure 2: Generation of the GHSR-A203E and GHSR-A203E-null mouse models. (A) Schematic diagram of the derivation of the GHSR-A203E and GHSR-A203E-null mouse models by homologous recombination. (B) Hypothalamic expression of food intake- and body weight-related transcripts in 66-week-old mice (n = 7–9 per group). (C) Pituitary expression of GH secretion-related transcripts in 14-week-old males (n = 3 per group). Data were analyzed by unpaired Student’s t-test. *P = 0.051.
mice were measured using calipers. In Copenhagen (Figure 7B–C), a separate cohort of 9-12-week-old male mice was individually housed within a 16-chamber indirect calorimetry system (PhenoMaster; TSE Systems, Bad Homburg, Germany) after 4 d in an identical set of acclimation cages. The mice received s.c. injections of either ghrelin (Polypeptide, Inc., Hillerød, Denmark) (2 mg/kg vs saline in a crossover fashion between 10.30 and 11.00 am, with a 2 d intervening period). Food intake and the respiratory exchange ratio (RER) were determined 2 h after the injections.

2.9. Administered ghrelin-induced GH secretion
In Copenhagen, ghrelin- and GHRH-induced GH secretion were assessed in a new cohort of male mice aged 7 and 10 weeks, respectively. Fifteen minutes after anesthesia with pentobarbital (i.p. 50 mg/kg body weight), ghrelin (0.5 mg/kg i.p.; Polypeptide, Inc.) or GHRH (0.5 mg/kg i.p.; Phoenix Pharmaceuticals, Karlsruhe) were injected. Blood was sampled from the orbital sinus before and 5 min after injections, as previously described [40,41].

2.10. 7-d 60% caloric restriction protocol
In Dallas, 7-week-old male mice were individually housed for 1 week during which daily food intake was measured for 3 successive days to determine the mean usual daily intake for each mouse. The mice were weighed and blood glucose determined from tail nicks using a Contour Next blood glucose monitoring system (Bayer, Mishawaka, IN, USA) daily 30 min before lights out. The mice were provided access to 40% of their usual daily calories in the form of their usual diet for 7 d beginning 15 min before lights out as previously described [42]. Body composition was determined using an EchoMRI (Echo Medical Systems, Houston, TX, USA) at the start of the experiment and again on days 4 and 6. Blood for GH and ghrelin determinations was collected on days 0, 5, and 7 by quick superficial temporal vein (submandibular)
Figure 4: *Ex vivo* studies comparing electrophysiological properties of arcuate NPY neurons from wild-type vs GHSR-A203E littermates. (A) Representative NPY-GFP neurons from a wild-type mouse on an NPY-GFP background under (i) bright-field illumination and (ii) FITC (GFP) illumination. Complete dialysis of Alexa Fluor 350 from the intracellular pipette is shown in (iii). A merged image of the targeted NPY neuron is shown in (iv). Arrow indicates the targeted cell. Scale bar = 50 µm. (B) Representative NPY-GFP neuron from a GHSR-A203E mouse on an NPY-GFP background under (i) bright-field illumination and (ii) FITC (GFP) illumination. Complete dialysis of Alexa Fluor 594 from the intracellular pipette is shown in (iii). A merged image of the targeted NPY neuron is shown in (iv). Arrow indicates the targeted cell. Scale bars = 50 µm. (C and D) Representative current-clamp recordings of NPY neurons from (C) wild-type and (D) GHSR-A203E mice demonstrating resting membrane potentials and depolarization upon addition of ghrelin (100 nM). (E) Change in membrane potential in NPY neurons from wild-type or GHSR-A203E mice in response to ghrelin (100 nM) or vehicle (ACSF). Data were analyzed by 2-way ANOVA followed by a Tukey post hoc analysis. **P < 0.01. (F–G) Linear regression analyses of current−voltage (I–V) plots of (F) wild-type (G) and GHSR-A203E mice.
Figure 5: Metabolic phenotype of wild-type and GHSR-A203E littermates. (A–B) Body weight, (C–D) % weight gain, (E–F) food intake, (G–H) food intake/body weight, and (I–J) cumulative feed efficiency in male (A, C, E, G, and I) and female (B, D, F, H, and J) wild-type (n = 7–9) and GHSR-A203E (n = 10–12) littermates. (K–L) Nose-anus body lengths in 26-week-old male (K) (n = 8–10) and 25-week-old female (L) (n = 9–12) mice. (M) Femur length in 26-week-old male (n = 8–10) mice. Data were analyzed by (A–J) repeated measures 2-way ANOVA followed by a Tukey post hoc analysis or (K–M) Student’s unpaired t-test. *P < 0.05, **P < 0.001, ***P < 0.0001, #P < 0.1, and n.s. = non-significant.
Figure 6: Metabolic effects of the GHSR-A203E mutation in older mice. (A) Body weights of male mice aged 21–66 weeks of age (n = 7–10). (B) Body lengths of male mice at 3 different ages (n = 7–9). (C) Femur lengths of male mice at 65–66 weeks of age (n = 6–8). Data were analyzed by (A–B) repeated measures 2-way ANOVA followed by Sidak’s multiple comparison post hoc analysis or by (C) an unpaired Student’s t-test. *P < 0.05, ****P < 0.0001.

Figure 7: In vivo effects of administered ghrelin in wild-type and GHSR-A203E littermates. (A) Ghrelin (0 (saline), 0.1, and 1 mg/kg s.c.)-induced 2 h food intake in 25-week-old male mice (n = 7–10). (B–C) Ghrelin (2 mg/kg s.c.)-induced (B) 2 h food intake and (C) RER (2 h after ghrelin administration) in 9–12-week-old male mice (n = 6–7). (D) Ghrelin (0.5 mg/kg i.p.)-induced GH secretion in 7-week-old mice (n = 3–4). (E) GHRH (0.5 mg/kg i.p.)-induced GH secretion in 10-week-old mice (n = 7). (F) Plasma IGF-1 (n = 6–8) and (G) pituitary GH content (n = 5–8) in 66-week-old mice. Data were analyzed by (A) a 2-way ANOVA followed by a Tukey post hoc analysis, (B–E) a 2-way repeated measures ANOVA followed by a Sidak’s multiple comparison post hoc analysis, or (F–G) an unpaired Student’s t-test. *P < 0.05, **P < 0.01, ****P < 0.0001, #P < 0.05, and n.s. = non-significant.
bleed into ice-cold EDTA-coated microtubes immediately after assessing blood glucose.

### 2.11. Hormone levels

For plasma ghrelin levels, p-hydroxymercuribenzoic acid was added (final concentration 1 mM) to EDTA-treated blood, tubes were centrifuged, and HCl was added (final concentration 0.1 N) prior to storage at −80 °C. No further processing of the EDTA-treated blood was performed prior to GH or IGF-1 determinations. To measure pituitary GH levels, pituitaries were lysed using RIPA lysis buffer [1% Triton X-100, 150 mM NaCl, 10 mM Tris–HCl (pH 7.5), 1 mM EDTA, 1% NP-40, and complete mini Protease Inhibitor Cocktail; Roche, Mannheim, Germany] and homogenized using a Qiagen TissueLyser II (Germantown). Ghrelin, GH, and IGF-1 levels were measured using commercial ELISA kits (EZRGRA-90K, EMD Millipore, Billerica, MA, USA; E2RMGH-45K, EMD Millipore; 22-IG1MS-E01, ALPCO, Reutlingen, Germany). The endpoint calorimetric assays were conducted using a PowerWave XS Microplate spectrophotometer and KC4 Junior software (BioTek Instruments, Winooski, VT, USA) or ClarioStar software version 5.40R2 and Mars software version 3.3 (BMG LabTech, Ortenberg, Germany).

### 2.12. Quantitative PCR

Hypothalamic RNA (from 66-week-old mice as previously described) and pituitary RNA (from 14-week-old mice) was extracted using an RNeasy Micro Kit (Qiagen). RNA concentrations were measured using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific). RNA samples were reverse transcribed to cDNA using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). The mix was incubated at 25 °C for 5 min, 50 °C for 60 min, and 70 °C for 15 min using Eppendorf Vapo-Protect Mastercycler. The cDNA samples were diluted 20x in sterile water and stored at −20 °C until further analysis. The diluted CDNA samples were mixed with PrecisionPLUS qPCR Master Mix (Primerdesign Ltd., Southampton, UK) according to the manufacturer’s description. The samples were run using a LightCycler 480 Instrument II (Roche, Basel, Switzerland), LightCycler 480 software.
version 1.5.1.62, and the delta–delta Ct method using GAPDH as a housekeeping gene to quantify the mRNA expression. The following PCR primers designed with Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/) were used: GHSR (5'-AAATGCTTGTGCTGCTGTT-3', 5'-AAGGAGGAGGTGAGGTGCTGTA-3'), GH (5'-CTAACGAGGTTCACTCTGTC-3', 5'-CTAGCTGATGCTGCTGCTGCT-3'), UCP2 (5'-CCTACGACGGGTCACTCTGTC-3', 5'-GGAATGGGCTGGTCTACGTA-3'), SSTR2 (5'-TTTGAACTGACGGTCTGTCTGCT-3', 5'-GGAAGGAAGGCTGCTCAGGTA-3'), SSTR5 (5'-TGTGTCGGGCTGCTGCTGCTGTA-3', 5'-GGGCTCCTGGGTAGGGG-3'), NPY (5'-TGGACTGACCCTCGCTCTAT-3', 5'-GCTGAAAGCTTCATCCTTGG-3'), POMC (5'-AGAGAGCTGCCTTTCCGCGAC-3', 5'-ACAGGCAAGGAAGAAGAAGG-3'), GHHR (5'-CCCAAAATTATGCCCGCCAAAC-3', 5'-GCTGAAAGGCTGCTGCTGCTGTA-3'), and GAPDH (5'-AAAGGGCTCATAACGACAGTC-3', 5'-GGAATGGGCTGGTCTACGTA-3').

2.13. Statistical analyses
Analyses were conducted using the tests indicated in the figure legends via GraphPad Prism 6.0 (Graph-Pad Software, San Diego, CA, USA) or NCSS 2007 (NCSS Statistical Software, Kaysville, UT, USA). All of the data were first subjected to Grubbs’ outlier test. Data are expressed as mean ± SEM. P values < 0.05 were considered statistically significant, and values 0.05 ≤ P < 0.1 were considered evidence of statistical trends.

3. RESULTS
3.1. The GHSR-A203E mutant lacks constitutive GHSR activity but retains ghrelin-dependent GHSR activity in heterologous expression systems
We measured the IP3 accumulation in COS-7 cells transiently transfected with constructs encoding mouse wild-type GHSR (GHSR-WT) or GHSR-A203E. As shown previously for the corresponding human constructs [14], in the absence of ghrelin, cells expressing GHSR-A203E accumulated less basal IP3 than cells expressing wild-type GHSR-WT (5'-TGGACTGACCCTCGCTCTAT-3', 5'-GCTGAAAGCTTCATCCTTGG-3'). As shown previously for the corresponding human constructs [14], in the absence of ghrelin, cells expressing GHSR-A203E accumulated less basal IP3 than cells expressing wild-type GHSR-WT (5'-TGGACTGACCCTCGCTCTAT-3', 5'-GCTGAAAGCTTCATCCTTGG-3'). The barium current densities in barium current expressing barium current systems were significantly increased compared to those in wild-type neurons (Figure 1B and C). Thus, GHSR-A203E mice express barium current in GHSR-A203E-null neurons was similar to that observed in the related GHSR-A203E-null mice (Figure 3C and D). Thus, the substitution of GHSR-A203E for wild-type GHSR in hypothalamic neurons that normally express GHSR-A203E increased barium current (similar to the effect of GHSR-A203E deletion) but maintained the capacity to inhibit calcium current in response to applied ghrelin (similar to the effect of ghrelin in neurons from the wild-type mice).

3.2. A newly generated novel GHSR-A203E mouse model expresses GHSR-A203E in place of GHSR-WT
The remaining studies utilized a novel mouse model expressing GHSR-A203E instead of GHSR-WT. To generate these mice, we inserted aloxP-flanked transcriptional blocking cassette (TBC) into an intron located downstream of the transcriptional start site upstream of the ketogenic start site of the mouse Ghsr gene. Additionally, we mutated the codon for alanine at position 203 to encode glutamate. Mice harboring two copies of the GHSR-A203E gene with the upstream loxP-flanked TBC are hereafter referred to as GHSR-A203E-null mice; these mice express neither GHSR-WT nor GHSR-A203E. These mice were crossed with Zp3-cre mice [34] to remove the TBC. Mice harboring two copies of the GHSR-A203E gene with the TBC deleted are hereafter referred to as GHSR-A203E mice; these mice expressed GHSR-A203E instead of GHSR-WT (Figure 2A).

3.3. Cultured hypothalamic neurons from GHSR-A203E mice lack constitutive GHSR activity but retain ghrelin-dependent GHSR activity
We assessed native calcium currents in cultured mediodiastal hypothalamic neurons from the GHSR-A203E mice, GHSR-A203E-null mice, and wild-type littermates by measuring barium current densities at baseline and in response to ghrelin. This region contains a dense population of arcuate NPY neurons, which represent a well-established site of GHSR expression [43,44]. The barium current densities in GHSR-A203E neurons were similar to those in GHSR-A203E-null neurons but significantly increased compared to those in wild-type neurons (Figure 3A and B). This increased calcium current within GHSR-A203E-null mice (Figure 2B and C). Thus, GHSR-A203E mice express GHSR-A203E at levels similar to those of wild-type GHSR in wild-type mice. Furthermore, the GHSR-A203E mutation alters hypothalamic POMC and pituitary GH mRNA expression, without effects on a selected set of related transcripts.

3.4. Arcuate hypothalamic NPY neurons harboring the GHSR-A203E mutation exhibit hyperpolarized membrane potentials yet retain ghrelin responsivity
We conducted whole-cell patch-clamp recordings on two sets of hrGF-labeled arcuate NPY neurons in brain slices from the wild-type and GHSR-A203E littermates (Figure 4A and B). GHSR-expressing arcuate NPY neurons depolarized upon ghrelin exposure [43,44]. The first set included 39 wild-type and 38 GHSR-A203E neurons. The GHSR-A203E mice were hyperpolarized compared to the wild-type neurons (wild-type mice: resting membrane potential = -40 ± 1.1 mV, input resistance 1.3 ± 0.1 GΩ, and whole-cell capacitance 11.3 ± 0.4 pF vs GHSR-A203E mice: resting membrane potential = -46 ± 0.7 mV, input resistance 1.3 ± 0.1 GΩ, and whole-cell capacitance 11.5 ± 0.5 pF). The second set was tested for ghrelin-induced changes and included 20 wild-type and 15 GHSR-A203E mice. Ghrelin depolarized 40% of arcuate NPY neurons from both wild-type and GHSR-A203E littermates (Figure 4C–E). The second set's ghrelin-responsive neurons were hyperpolarized at baseline in the GHSR-A203E mice compared to wild-type mice (wild-type mice: resting membrane potential = -40 ± 1.1 mV, input resistance 1.3 ± 0.1 GΩ, and whole-cell capacitance 11.3 ± 0.4 pF vs GHSR-A203E mice: resting membrane potential = -46 ± 0.7 mV, input resistance 1.3 ± 0.1 GΩ, and whole-cell capacitance 11.5 ± 0.5 pF).
resting membrane potential was $-45 \pm 1.3$ mV, input resistance $1.3 \pm 0.1$ GΩ, and whole-cell capacitance $12.6 \pm 0.9$ pF vs GHSR-A203E mice: resting membrane potential was $-49 \pm 2.2$ mV, input resistance $1.2 \pm 0.1$ GΩ, and whole-cell capacitance $11.0 \pm 1.0$ pF). The lower resting membrane potential in the ghrelin-responsive GHSR-A203E neurons likely contributed to their enhanced ghrelin-induced change in membrane potential (Figure 4E). The mean ghrelin-induced action potential frequencies in the GHSR-A203E neurons vs wild-type neurons were similar (data not shown). Thus, constitutive GHSR activity contributed to a native depolarizing conductance in the arcuate NPY neurons. Also, ghrelin depolarized the same percentage of arcuate NPY neurons in the GHSR-A203E mice as in the wild-type littermates.

Rectangular current steps ($\pm 50$ pA at 400 ms) were applied to the plasma membranes of the arcuate NPY neurons to obtain current—voltage (I–V) plots. The depolarization was concomitant with a decrease in input resistance (wild-type mice: $38.5\%$, $n = 3$, and $1.3 \pm 0.2$ GΩ for ACSF control; $0.8 \pm 0.1$ GΩ for ghrelin, Figure 4F vs GHSR-A203E mice: $35.7\%$, $n = 3$, and $1.4 \pm 0.1$ GΩ for ACSF control; and $0.9 \pm 0.1$ GΩ for ghrelin, Figure 4G). Subsequent linear regression analysis revealed the reversal potential of the ghrelin-induced depolarization was $-23 \pm 2.7$ mV in the wild-type mice and $-20 \pm 4.7$ mV in the GHSR-A203E mice (Figure 4F and G). This suggests that a putative non-selective cation conductance may have been involved in the ghrelin-induced depolarization of the arcuate NPY neurons [45–47].

3.5. GHSR-A203E mice develop reduced body weight and body length when aged

We monitored the weekly body weights and food intake of individually housed male and female GHSR-A203E and wild-type littermates with ad libitum access to regular chow for 21 weeks beginning at 4 weeks of age. No genotype-dependent differences in body weights were observed over the course of the study (Figure 5A and B), although the GHSR-A203E mice gained slightly less body weight (Figure 5C and D). Weekly food intake over the course of the study was slightly greater in the GHSR-A203E mice (Figures 5E–H). Cumulative feed efficiency (defined as body weight gain per kilocalories of food consumed) was slightly lower over the course of the study in male GHSR-A203E mice but not females (Figure 5I and J). Body lengths (Figures 5K and L) and femur lengths (Figure 5M) at the end of the 21-week study were genotype-independent.

We also monitored the weekly body weights in a second cohort of individually housed male GHSR-A203E and wild-type littermates with ad libitum access to regular chow from 21-22 weeks of age until 65–66 weeks of age. Although the starting body weights of the two genotypes had no statistically significant differences, they gradually diverged, leading to lower body weights for the GHSR-A203E mice (Figure 5A). Similarly, although the body lengths of the two genotypes had no statistically significant differences at 21–22 or 32–33 weeks of age, by 65–66 weeks of age, the GHSR-A203E mice had shorter body lengths (Figure 5B). The femur lengths of the 65–66 week old GHSR-A203E mice were also shorter than those of their wild-type littermates (Figure 6C).

Thus, while the GHSR-A203E mutation did not affect body weight, body length, or femur length in a statistically significant manner in the first 6 months of life, it was associated with decreased body weight, body length, and femur length in mice aged >1 year. This was despite slightly increased food intake in younger GHSR-A203E mice, albeit younger male mice also gained slightly less weight per food consumed.

3.6. Orexigenic and GH secretagogue effects of administered ghrelin are blunted in GHSR-A203E mice

We assessed the acute food intake responses to administered ghrelin. In a first set of mice (25-week-old male GHSR-A203E and wild-type littermates individually housed in their home cages), ghrelin dose-dependently increased 2 h food intake over that induced by saline in the wild-type mice but not in their GHSR-A203E littermates (Figure 7A). A similar observation was made for ghrelin using a single, higher dose in a second set of mice (9–12-week-old male GHSR-A203E and wild-type littermates individually housed in metabolic chambers) (Figure 7B). The corresponding respiratory exchange ratio (RER) values increased in the wild-type mice administered ghrelin but not in the GHSR-A203E mice (Figure 7C).

We also assessed GH secretion in response to administered ghrelin in the GHSR-A203E mice and their wild-type littermates. Whereas ghrelin markedly increased plasma GH in the wild-type mice compared to saline, its GH secretagogue efficacy was dramatically reduced (although still present) in the GHSR-A203E mice (Figure 7D). In contrast, GHRH, which increases GH release in a GHSR-independent manner, increased the plasma GH levels in both the wild-type and GHSR-A203E mice (Figure 7E).

We also measured plasma IGF-1 and pituitary GH content from the previously described cohort of 65–66-week-old GHSR-A203E and wild-type littermates. Following an overnight fast, plasma IGF-1 was lower while pituitary GH content was higher in the GHSR-A203E mice (Figure 7F and G).

These data suggest that the GHSR-A203E mice were resistant to the usual acute orexigenic and GH secretagogue actions of administered ghrelin. Also, seemingly coinciding with the decreased body length and femur length in the aged GHSR-A203E mice, the plasma levels of the downstream GH effector IGF-1 were lower although the pituitary GH content was higher, suggesting a possible defect in GH release and an ensuing decrease in IGF-1 recruitment in the GHSR-A203E mice.

3.7. GHSR-A203E mice submitted to a caloric restriction protocol exhibit a markedly blunted GH response and an exaggerated drop in blood glucose

We submitted the GHSR-A203E and wild-type littermates to a week-long, severe caloric restriction protocol in which the mice were provided access to only 40% of their usual daily calories. This protocol induced progressive elevations in plasma GH in the wild-type mice but not in the ghrelin-knockout or ghrelin O-acyltransferase-knockout mice [48,49]. These increases in GH help prevent the development of life-threatening hypoglycemia that is otherwise observed in mice lacking ghrelin, ghrelin O-acyltransferase, GHSR, ghrelin cell [h]-adrenergic receptors, or hepatic GH receptors, mice lacking ghrelin cells, and mice overexpressing LEAP2 [24,42,48–53]. Over the course of the 7-d regimen, no genotype-dependent differences in body weight or body composition were observed (Figure 8A–C). Plasma GH increased only in the wild-type mice, plasma ghrelin increased in a genotype-independent manner, and a more precipitous decrease in blood glucose was noted in the GHSR-A203E mice (Figure 7D–F).

Additionally, although not statistically significant, a genotype-dependent difference in survival was noted, and 3 of 20 of the GHSR-A203E mice died whereas none of the 9 wild-type littermates died (Figure 7G).

4. DISCUSSION

In the current study, we used in vitro, ex vivo, and in vivo methods to assess the physiological significance of constitutive GHSR activity. This
study was based on published work using in vitro heterologous cell expression systems, which suggested that the naturally occurring GHSR-A204E mutation associated with short stature in humans impairs constitutive (ghrelin-independent) GHSR activity while retaining ghrelin-dependent GHSR activity. For the current study, we used the mouse GHSR-A203E correlate of the human GHSR-A204E mutation. When comparing the phenotype of the GHSR-A203E mice to that of human carriers of the GHSR-A204E mutation, similarities in body length and GH deficiency were observed. The human GHSR-A204E mutation is associated with a high penetrance of short stature, which might be assumed to result from impaired GH secretion due to the mutant GHSR [21,28]. Such was the case in two of the four GHSR-A204E carriers with short stature in whom GH and IGF-1 were reported: a low GH peak and low IGF-1 were observed in one subject and a low GH peak but normal IGF-1 were observed in a second subject; however, the remaining two subjects had normal GH peaks and IGF-1 [28]. Three of those subjects received GH treatment, and as a result, increased their growth velocity [28]. Reminiscent of the highly penetrant short stature phenotype in human GHSR-A204E carriers, here we showed that GHSR-A203E mutant mice exhibited slight albeit statistically significant reductions in body length and femur length by 65–66 weeks of age (4.3% and 2.6%, respectively). Differences in these parameters were not observed at 25 weeks of age, however, which contrasts with the GHSR-A204E-associated growth deficiency in human carriers, which was observed in childhood [28].

Also reminiscent of the GH deficiency observed in at least some of the human GHSR-A204E carriers, plasma IGF-1 was reduced in overnight-fasted 65–66-week-old GHSR-A203E mice. Additionally, over the course of a 7-d 60% caloric restriction that usually (in wild-type mice) leads to progressive GH elevation, the GHSR-A203E mice lacked any substantial increase in GH release. The exaggerated drop in blood glucose observed during the caloric restriction protocol paralleled the life-threatening severe hypoglycemia previously observed in other genetic mouse models of reduced GHSR signaling or hepatic GH action [24,42,48–53]. Similarly, in the GHSR-A203E mice, administered ghrelin-induced GH secretion was negligible, while GHRH-induced GH secretion was intact. These findings, in conjunction with increased GH protein content observed in pituitaries of GHSR-A203E mice and intact GHRH-induced GH release by GHSR-A203E mice, suggest a pattern of defective GH secretion resulting from defective signaling by the GHSR-A203E mutant.

However, the body weight phenotype of the GHSR-A203E mice did not match that attributed to the GHSR-A204E mutation in humans. As mentioned, several family members with the GHSR-A204E mutation and an unrelated GHSR-A204E carrier have overweight or obesity [28,29]. However, the body weight curves of the GHSR-A203E mice and wild-type littermates overlapped from 4–25 weeks of age and eventually diverged with increasing age, such that by 65–66 weeks of age, the GHSR-A203E mice were ~19.7% lighter than the wild-type mice. Supporting the development of reduced body weight in the aged GHSR-A203E mice, a subtle reduction in body weight gain was already apparent in the younger GHSR-A203E mice as was a subtle reduction in cumulative feed efficiency (in the males). Nonetheless, the younger GHSR-A203E mice exhibited increased food intake compared to the wild-type littermates. Notwithstanding the observation of overweight and obesity in many human GHSR-A204E carriers, the reduction in body weight observed in the GHSR-A203E mice fits better with the body weight phenotype expected upon reduced GHSR signaling. Our finding in mice suggests that the overweight and obesity phenotype of some human GHSR-A204E carriers is unrelated to the mutation [21].

Perhaps the greatest surprise in our current study relates to the seemingly discrepant observations of preserved ghrelin-dependent GHSR activity in vitro and ex vivo vs absent or markedly reduced ghrelin-dependent GHSR activity in vivo. Specifically, baseline Gαq-mediated IP3 accumulation was lower in COS-7 cells transfected with GHSR-A203E than in those transfected with GHSR-WT while ghrelin-induced IP3 accumulation was observed in cells transfected with either construct. Also, basal reduction in Ca2+,2 current density in Ca2+,2-expressing HEK293T cells transfected with GHSR-WT was reversed by GHSR-A203E while ghrelin-induced inhibition of Ca2+,2 current density was observed in cells transfected with either construct. These in vitro findings were similar to those observed previously for the human GHSR-A204E construct [10] and were further supported by our ex vivo evaluation of neurons from the wild-type mice, GHSR-A203E mice, and GHSR-A203E-null mice. In cultured hypothalamic neurons from the GHSR-A203E mice and GHSR-deficient mice, native calcium currents increased compared to the wild-type mice whereas in cultured hypothalamic neurons from the GHSR-A203E mice and wild-type mice, ghrelin inhibited calcium currents. Also, in the brain slices, resting membrane potentials of the arcuate NPY neurons from the GHSR-A203E mice were hyperpolarized compared to those from the wild-type mice, yet the same percentage of these neurons from the GHSR-A203E and wild-type mice depolarized upon ghrelin exposure. As such, the in vitro and ex vivo studies clearly distinguished the effects of the A203E mutation on constitutive vs ghrelin-dependent GHSR activity and, in so doing, demonstrated a loss of constitutive GHSR activity but retained ghrelin-induced activity. However, the in vivo studies were not in agreement: administered ghrelin exhibited absent orexigenic efficacy and markedly reduced GH secretagogue efficacy in the GHSR-A203E mice. Parenthetically, it might be of interest in future studies to determine if GHSR-A203E mice would respond more robustly to higher doses of administered ghrelin.

Thus, the ex vivo results support the conclusions that constitutive GHSR activity contributes to the native depolarizing conductance of GHSR-expressing arcuate NPY neurons and that the A203E mutation ablates constitutive GHSR activity (as those assessments were made in cells that normally express GHSR and in preparations without ghrelin). However, given the reduced responses to administered ghrelin in vivo in the GHSR-A203E mice, it is uncertain whether the reduced body weight and body length observed in the GHSR-A203E mice following the long-term feeding study or the exaggerated decrease in blood glucose and markedly attenuated GH elevation observed in the GHSR-A203E mice during the 7-d 60% caloric restriction study are solely due to the loss of constitutive GHSR activity or also to deficient ghrelin-dependent GHSR activity. Indeed, the severe caloric restriction protocol was associated with an equivalently progressive increase in ghrelin over its week-long course in both the GHSR-A203E and wild-type littermates.

There are several potential reasons for this discrepancy. First, in vitro studies are by nature artificial. As such, the effects on the signaling molecules studied may not represent the effects on the actual signaling molecules that interact with GHSR within cells that express GHSR normally. Also, the expression levels of wild-type GHSR or the GHSR-A203E mutant in the transfected cells may have differed from those in cells that express GHSR normally. Additionally, the expression levels of proteins that interact with GHSR, such as melanocortin receptor accessory protein-2 (MRAP2) may have differed in the transfected cells from those in native GHSR-expressing cells. MRAP2 affects GHSR activity in many ways and is required for ghrelin-induced food intake [54,55]. More specifically, MRAP2 potentiates ghrelin-dependent GHSR signaling via Gαq-mediated IP3 accumulation, inhibits
constitutive GHSR signaling via Gαq, and decreases ghrelin-stimulated β-arrestin recruitment [54,55]. Also, co-transfection of CHO cells with human GHSR-A204E + MRP2 markedly reduces ghrelin-dependent IP accumulation over that in cells transfected with GHSR-A204E alone [55]. Thus, differential expression levels of MRP2 in the COS-7 and HEK293T cells used in this study vs those occurring naturally in cells that normally express GHSR could have contributed to the seemingly different results observed in vitro vs in vivo for both GHSR-WT and GHSR-A203E. As another example, previous studies revealed that GHSR forms heterodimers with other GPCRs, including MC3R, dopamine D1R, and dopamine D2R, among others [56–58]. For instance, MC3R has been localized to most GHSR-expressing neurons in the arcuate nucleus [57]. Co-transfection of COS-7 and HEK293 cells with both GHSR-WT + MC3R diminishes GHSR constitutive signaling and ghrelin-dependent GHSR signaling [57]. Differential expression levels of heterodimer-forming GPCRs such as MC3R in transfected cells vs naturally GHSR-expressing cells are undoubtedly present.

Second, focusing on one or two signaling systems in transfected cells, as we did in this study, may not tell the whole story. For instance, in previous in vitro studies with the human GHSR-A204E mutant, while certain aspects of GHSR activity were preserved upon application of ghrelin (such as Gαq-mediated IP accumulation, as was also observed in this study using mouse GHSR-A203E), β-arrestin recruitment (which was reduced dramatically at baseline) could not be rescued by application of ghrelin [14]. Additionally, the previously described heterodimerization of GHSR with other GPCRs also affects signaling via those other GPCRs. For instance, co-transfection of GHSR + MC3R enhances α-MSH signaling via MC3R-engaged, Gαq-mediated cAMP accumulation [57]. Substitution of GHSR-A204E for wild-type GHSR leads to reduced α-MSH-induced cAMP accumulation [57]. Thus, while our newly reported effects of the GHSR-A203E mutation ± ghrelin on IP3 accumulation and calcium currents in vitro suggest impaired constitutive GHSR activity and retained ghrelin-dependent GHSR activity, had additional signaling systems been tested, deficiencies in ghrelin-dependent GHSR activity may have been uncovered.

Third, while ex vivo systems avoid the artificial aspects of transfection studies, focusing on the activity of the GHSR-A203E mutation in only hypothalamic neurons, as we did in this study, may miss effects of the mutation in other sites of GHSR expression. For example, ghrelin’s orexigenic actions are distributed over several GHSR-expressing brain regions and neuronal cell types, including the caudal brainstem, midbrain, and hippocampus in addition to several hypothalamic nuclei [59–61]. Different subsets of these regions and others are likely responsible to varying degrees for the ghrelin system’s other actions [62]. Ghrelin and the endogenous GHSR antagonist/inverse agonist LEAP2 may penetrate these different brain regions to varying degrees. As such, it is not necessarily the case that ghrelin-dependent and constitutive GHSR activity are engaged to the same relative degrees from one brain region to another or that ghrelin-dependent vs constitutive GHSR activity are relevant in all brain regions.

5. CONCLUSIONS

In vitro, ex vivo, and in vivo methods were used to investigate the physiological significance of the GHSR-A203E mutation, a correlate of the naturally occurring human GHSR-A204E mutation associated with a highly penetrant occurrence of short stature, GH deficiency, and occasional overweight or obesity. Our in vitro and ex vivo studies with mouse GHSR-A203E confirmed previous in vitro studies with a human GHSR-A204E construct, which demonstrated the loss of constitutive GHSR activity but retained ghrelin-dependent GHSR activity. Reminiscent of the short stature and GH deficiency in human carriers, mice expressing GHSR-A203E instead of wild-type GHSR exhibited decreased body length and femur length when aged over one year and defective GH secretion in response to a 7–60% caloric restriction protocol. Unlike human carriers who were overweight and obese, the aged GHSR-A203E mice attained less body weight than wild-type littermates. Importantly, unlike the in vitro and ex vivo studies demonstrating retained ghrelin-dependent GHSR activity, the GHSR-A203E mice exhibited a loss of administered ghrelin-induced food intake and a marked attenuation of administered ghrelin-induced GH release. Thus, based on our ex vivo studies, we can definitively state that constitutive GHSR activity contributes to native depolarizing conductance in arcuate NPY neurons. Also, based on our in vivo studies, we can definitively state that the GHSR-A203E mutation causes reduced body length, defective GH release, and diminished body weight. However, discrepancies in ghrelin-dependent GHSR-A203E activity as determined using the in vitro and ex vivo models vs the in vivo model prevented us from attributing the phenotype of the GHSR-A203E mice, and by extension, the phenotype of human carriers of the GHSR-A204E mutation, solely to defective constitutive GHSR activity.

AUTHOR CONTRIBUTIONS

L.J.T., S.O.-L., J.R., Z.H., M.P.C., E.R.M., C.J., N.P., M.N., M.A.H., V.M.D., N.P.M., and B.K.M. conducted the experiments. J.R., M.P., K.W.W., B.H., and J.M.Z. supervised the experiments. L.J.T., J.R., M.P., K.W.W., B.H., and J.M.Z. wrote the manuscript. B.H. and J.M.Z. conceived the study.

ACKNOWLEDGMENTS

This study was supported by the NIH (R01DK103884 to J.M.Z., P01DK119130 to J.M.Z. and K.W.W., and R01DK119130 to K.W.W.), the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen (to B.H. and J.M.Z.), and grants from the Fondo para la Investigación Científica y Tecnológica (PICT2016-1084 and PICT2017-3196 to M.P. and PICT2015-3330 and PICT2017-0602 to J.R.). We thank Dr. Guadalupe García Romero and Dr. Silvia Rodríguez (IMBICE) for their technical assistance, Drs. Diane Lipscombe, Jacky Marie, Silvia Rodríguez, and Joel Elmqquist for providing reagents, and the UT Southwestern Medical Center Transgenic Core Facility for their assistance in generating the GHSR-A203E mouse line.

CONFLICT OF INTEREST

None declared.

REFERENCES

[1] Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., Kangawa, K., 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660.
[2] Mani, B.K., Zigman, J.M., 2017. Ghrelin as a survival hormone. Trends in Endocrinology and Metabolism 28:843–854.
[3] Muller, T.D., Naguerais, R., Andermann, M.L., Andrews, Z.B., Anker, S.D., Argente, J., et al., 2015. Ghrelin. Molecular and Metabolism 4:437–460.
[4] Holst, B., Schwartz, T.W., 2004. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends in Pharmacological Sciences 25:113–117.
Lopez Soto, E.J., Agosti, F., Cabral, A., Mustafa, E.R., Damonte, V.M., presenta evidencia de que el sistema de ghrelin tiene la capacidad de regular los comportamientos de alimentación a pesar de fluctuaciones espaciales en el sistema GHSR y su endógena ligand. International Journal of Molecular Sciences 18.

Schalla, M.A., Stengel, A., 2019. Modulación farmacológica de ghrelin para inducir pérdida de peso: éxitos y desafíos. Current Diabetes Reports 19:102.

Mear, Y., Enjalbert, A., Thirion, S., 2013. GH-SR1a constitutiva actividad y su relevancia fisiológica. Frontiers in Neuroscience 7:87.

Holst, B., Cygankiewicz, A., Jensen, T.H., Ankersen, M., Schwartz, T.W., 2003. Alta constitutiva señalización del receptor de ghrelin identificación de un potencial antagonista. Molecular Endocrinology 17:2291–2210.

Liu, G., Fortin, J.P., Beinborn, M., Kopin, A.S., 2007. Cuatro mutaciones que inducen pérdida de peso: éxitos y desafíos. Proceedings of the National Academy of Sciences of the United States of America 115:E10255–E10264.

Ge, X., Yang, H., Bednarek, M.A., Galon-Tilleman, H., Chen, P., Chen, M., et al., 2018. Traducción de señalización del receptor de ghrelin sistema en diferencial en diferentes funciones. Cell Metabolism 27:461–469 e468.

M’Kadmi, C., Cabral, A., Barrile, F., Giribaldi, J., Cantel, S., Damian, M., et al., 2019. N-terminal liver-expressed antimicrobial peptide 2 (LEAP2) región exhibe inverso antagonista actividad al receptor de ghrelin. Journal of Medicinal Chemistry 62:965–973.

Mari, B.K., Puzziferri, N., He, Z., Rodriguez, J.A., Osborne-Lawrence, S., Metzger, N.P., et al., 2019. LEAP2 cambios con cuerpo humano y enriquece en humanos y mice. Journal of Clinical Investigation 129:3909–3923.

Barrile, F., M’Kadmi, C., De Francesco, P.N., Cabral, A., Garcia Romero, G., Mustafa, E.R., et al., 2019. Desarrollo de un nuevo ligando de crecimiento hormonal secretagogo receptor basado en el N-Termal Leap2 región. Molecular and Cellular Endocrinology 498:110573.

Pantel, J., Legendre, M., Cabrol, S., Hilal, L., Hajj, Y., Morisset, S., et al., 2006. Auscultación de actividad constitutiva del crecimiento hormonal secretagogo receptor en portadores de acné. Journal of Clinical Investigation 116:760–768.

Wang, H.J., Geller, F., Dempfle, A., Schauble, N., Friedel, S., Lichtner, P., et al., 2004. Ghrelin receptor gene: identificación de varios sellos variables en extremadamente obesos niños y adolescentes, niños normales y en estudio de enfermedad. Journal of Clinical Endocrinology & Metabolism 91:197–192.

Inoue, H., Kangawa, K., Kino, O., Sakamoto, Y., Kimura, C., Horikawa, R., et al., 2011. Identificación y funcionamiento analítico de varias moléculas de crecimiento hormonal secretagogo receptor (GHSR) genes mutaciones en japoneses con acné. Journal of Clinical Endocrinology & Metabolism 96:E373–E378.

Sivertsen, B., Lang, M., Frimurer, T.B., Schwartz, T.W., Holst, B., 2012. Modulación de actividad constitutiva y señalización del receptor de ghrelin regulado por conformacional estabilidad en el segundo loop extracelular. Journal of Biological Chemistry 287:33488–33502.

Petersen, P.S., Woldbye, D.P., Madsen, A.N., Egerod, K.L., Jin, C., Lang, M., et al., 2009. En vivo caracterización de alta señalización desde el receptor de endocrino. Endocrinology 150:4920–4930.

Kemp, B.A., Howell, N.L., Glidea, J.J., Padia, S.H., 2014. Intrarenales reacciones de adelgazamiento prevenir alta ingesta de hormona en ratones de murciélago. Endocrinology 155:2658–2667.

Fernandez, G., Cabral, A., Andreoli, M.F., Labarthe, A., M’Kadmi, C., Ramos, J.G., et al., 2018. Evidencia de un papel en el receptor de hormona del crecimiento regulación de fisiología a través de alteraciones de secuencia. Journal of Biological Chemistry 289:469–204.

Mani, B.K., Puzziferri, N., He, Z., Rodriguez, J.A., Osborne-Lawrence, S., Metzger, N.P., et al., 2019. LEAP2 cambios con cuerpo humano y enriquece en humanos y mice. Journal of Clinical Investigation 129:3909–3923.

Barrile, F., M’Kadmi, C., De Francesco, P.N., Cabral, A., Garcia Romero, G., Mustafa, E.R., et al., 2019. Desarrollo de un nuevo ligando de crecimiento hormonal secretagogo receptor basado en el N-Termal Leap2 región. Molecular and Cellular Endocrinology 498:110573.

Pantel, J., Legendre, M., Cabrol, S., Hilal, L., Hajj, Y., Morisset, S., et al., 2006. Auscultación de actividad constitutiva del crecimiento hormonal secretagogo receptor en portadores de acné. Journal of Clinical Investigation 116:760–768.

Wang, H.J., Geller, F., Dempfle, A., Schauble, N., Friedel, S., Lichtner, P., et al., 2004. Ghrelin receptor gene: identificación de varios sellos variables en extremadamente obesos niños y adolescentes, niños normales y en estudio de enfermedad. Journal of Clinical Endocrinology & Metabolism 91:197–192.

Inoue, H., Kangawa, K., Kino, O., Sakamoto, Y., Kimura, C., Horikawa, R., et al., 2011. Identificación y funcionamiento analítico de varias moléculas de crecimiento hormonal secretagogo receptor (GHSR) genes mutaciones en japoneses con acné. Journal of Clinical Endocrinology & Metabolism 96:E373–E378.

Sivertsen, B., Lang, M., Frimurer, T.B., Schwartz, T.W., Holst, B., 2012. Modulación de actividad constitutiva y señalización del receptor de ghrelin regulado por conformacional estabilidad en el segundo loop extracelular. Journal of Biological Chemistry 287:33488–33502.

Petersen, P.S., Woldbye, D.P., Madsen, A.N., Egerod, K.L., Jin, C., Lang, M., et al., 2009. En vivo caracterización de alta señalización desde el receptor de endocrino. Endocrinology 150:4920–4930.

Kemp, B.A., Howell, N.L., Glidea, J.J., Padia, S.H., 2014. Intrarenales reacciones de adelgazamiento prevenir alta ingesta de hormona en ratones de murciélago. Endocrinology 155:2658–2667.

Fernandez, G., Cabral, A., Andreoli, M.F., Labarthe, A., M’Kadmi, C., Ramos, J.G., et al., 2018. Evidencia de un papel en el receptor de hormona del crecimiento regulación de fisiología a través de alteraciones de secuencia. Journal of Biological Chemistry 289:469–204.

Mani, B.K., Puzziferri, N., He, Z., Rodriguez, J.A., Osborne-Lawrence, S., Metzger, N.P., et al., 2019. LEAP2 cambios con cuerpo humano y enriquece en humanos y mice. Journal of Clinical Investigation 129:3909–3923.

Barrile, F., M’Kadmi, C., De Francesco, P.N., Cabral, A., Garcia Romero, G., Mustafa, E.R., et al., 2019. Desarrollo de un nuevo ligando de crecimiento hormonal secretagogo receptor basado en el N-Termal Leap2 región. Molecular and Cellular Endocrinology 498:110573.

Pantel, J., Legendre, M., Cabrol, S., Hilal, L., Hajj, Y., Morisset, S., et al., 2006. Auscultación de actividad constitutiva del crecimiento hormonal secretagogo receptor en portadores de acné. Journal of Clinical Investigation 116:760–768.

Wang, H.J., Geller, F., Dempfle, A., Schauble, N., Friedel, S., Lichtner, P., et al., 2004. Ghrelin receptor gene: identificación de varios sellos variables en extremadamente obesos niños y adolescentes, niños normales y en estudio de enfermedad. Journal of Clinical Endocrinology & Metabolism 91:197–192.

Inoue, H., Kangawa, K., Kino, O., Sakamoto, Y., Kimura, C., Horikawa, R., et al., 2011. Identificación y funcionamiento analítico de varias moléculas de crecimiento hormonal secretagogo receptor (GHSR) genes mutaciones en japoneses con acné. Journal of Clinical Endocrinology & Metabolism 96:E373–E378.

Sivertsen, B., Lang, M., Frimurer, T.B., Schwartz, T.W., Holst, B., 2012. Modulación de actividad constitutiva y señalización del receptor de ghrelin regulado por conformacional estabilidad en el segundo loop extracelular. Journal of Biological Chemistry 287:33488–33502.
He, Z., Gao, Y., Alhadeff, A.L., Castorena, C.M., Huang, Y., Lieu, L., et al., 2018. Cellular and synaptic reorganization of arcuate NPY/AgRP and POMC neurons after exercise. Molecular and Metabolism 18:107–119.

Sun, Y., Wang, P., Zheng, H., Smith, R.G., 2004. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proceedings of the National Academy of Sciences of the United States of America 101:4679–4684.

Holst, B., Madsen, K.L., Jansen, A.M., Jin, C., Rickhag, M., Lund, V.K., et al., 2013. PI3K1 deficiency impairs secretory vesicle biogenesis and leads to growth retardation and decreased glucose tolerance. PLoS Biology 11:e1001542.

Marin, B.K., Osborne-Lawrence, S., Vijayaraghavan, P., Hepler, C., Zignman, J.M., 2016. beta1-Adrenergic receptor deficiency in ghrelin-expressing cells causes hypoglycemia in susceptible individuals. Journal of Clinical Investigation 126:3467–3478.

Cowley, M.A., Smith, R.G., Diano, S., Tschop, M., Pronchuk, N., Grove, K.L., et al., 2004. Ghrelin stimulation of growth hormone acts on liver to stimulate autophagy, support glucose production, and preserve blood glucose in chronically starved mice. Proceedings of the National Academy of Sciences of the United States of America 116:7449–7454.

Wang, G., Liu, C., Uchida, A., Chuang, J.C., Walker, A., Liu, T., et al., 2014. Arcuate AgRP neurons mediate orexigenic and gluco-regulatory actions of ghrelin. Molecular and Metabolism 3:64–72.

Srisai, D., Yin, T.C., Lee, A.A., Rouault, A.A.J., Pearson, N.A., Grobe, J.L., et al., 2017. MRAP2 regulates ghrelin receptor signaling and hunger sensing. Nature Communications 8:713.

Fang, F., Shi, X., Brown, M.S., Goldstein, J.L., Liang, G., 2019. Growth hormone deficiency impairs secretory vesicle biogenesis and leads to decreased glucose tolerance. Proceedings of the National Academy of Sciences of the United States of America 116:2226–2231.

Gonzalez, J.C., Perollo, M., Sakata, I., Osborne-Lawrence, S., Savitt, J.M., Lutter, M., et al., 2011. Ghrelin mediates stress-induced food-reward behavior in mice. Journal of Clinical Investigation 121:2684–2692.